Prognostic Stage IV Breast Cancer AJCC v8 Recruiting Phase 2 Trials for Retifanlimab (DB15766)

IndicationStatusPhase
DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04445844INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyTreatment